Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rociletinib in EGFR Mutant NSCLC
NCT02705339Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- May 2016
- Primary completion
- Nov 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of rociletinib in non-small cell lung cancer (NSCLC), sponsored by Washington University School of Medicine. Planned start May 2016; status: withdrawn.
02
Drugs
rociletinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02705339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02705339.